[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amoxicillin-clavulanate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amoxicillin-clavulanate":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100548887","pediatric-antibiotic-dosing-in-extracorporal-membrane-oxygenation-padecmo-100548887",false,"NCT06426836","Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation","PADECMO","Inclusion Criteria:\n\n* patients admitted to the pediatric intensive care unit or cardiac intensive care unit\n* patient age : 1,8 kg-15 years\n* patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin)\n* intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)\n* extracorporeal membrane oxygenation circuit\n\nExclusion Criteria:\n\n* no catheter in place for blood sampling\n* absence of parental\u002Fpatient consent\n* known hypersensitivity to beta-lactam antibiotics and ciprofloxacin","ALL","15 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).",[27,28,29,30,31,32,33,34,35],"Pharmacokinetics","Amoxicillin-clavulanate","Piperacillin-tazobactam","Meropenem","Cefazolin","Teicoplanin","Vancomycin","Ciprofloxacin","Amikacin","RECRUITING","2026-01-15",{"date":39,"type":40},"2026-01-16","ACTUAL",{"date":42,"type":40},"2016-08-19",{"date":44,"type":21},"2026-07-01",{"name":46,"class":47},"University Hospital, Ghent","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100244176","antibiotic-dosing-in-pediatric-intensive-care-100244176","NCT02456974","Antibiotic Dosing in Pediatric Intensive Care","ADIC","Inclusion Criteria:\n\n* patients admitted to the pediatric intensive care unit\n* patient age\u002Fweight : 1,8 kg-15 years\n* patient receiving antibiotic treatment (piperacillin-tazobactam, amoxicillin-clavulanate, vancomycin, teicoplanin, meropenem, ciprofloxacin, amikacin) via intermittent infusion regimen or continuous infusion according to institutional treatment guidelines\n* intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)\n\nExclusion Criteria:\n\n* no catheter in place for blood sampling\n* absence of parental\u002Fpatient consent\n* known hypersensitivity to beta-lactam antibiotics, glycopeptides, fluoroquinolones, aminoglycosides\n* extracorporeal circuit (haemodialysis, ECMO, peritoneal dialysis )","1 Day","16 Years",{"count":58,"type":21},640,"3 Days","OBSERVATIONAL","Pharmacokinetics of antibiotics in critically ill neonates, infants and children",[27,28,29,33,32,30,34,35],{"date":39,"type":40},{"date":65,"type":4},"2012-05",{"date":67,"type":21},"2027-09-01",{"name":46,"class":47},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":69},"100587539","phase-4-precision-dosing-of-beta-lactam-antibiotics-in-critically-ill-children-100587539","NCT06929702","Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children","Early Model-Informed Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children: Big Solution for Small People?","MOMENTUM","Inclusion Criteria:\n\n* Subject aged between 0 - 17 years 10 months.\n* Subject admitted to a participating ward unit (Neonatal Intensive Care Unit, Pediatric Intensive Care Unit, Pediatric Hematology-Oncology unit).\n* Strongly suspected or confirmed systemic infection.\n* Subject planned to start on intravenous amoxicillin-clavulanic acid, piperacillin-tazobactam or meropenem treatment at least aimed for a minimum duration of two days at time of inclusion. If the subject was previously treated with the same beta-lactam, the minimum interval to the previous beta-lactam treatment episode is\n* 40 hours for amoxicillin-clavulanic acid (based on elimination half-life)\n* 8 hours for piperacillin-tazobactam and meropenem (based on elimination half-life) Subject planned to start on intravenous amoxicillin (without clavulanic acid) will not be included.\n* Informed consent\u002Fassent signed by parents or legal representatives of the subject.\n* Not previously enrolled in this trial.\n\nExclusion Criteria:\n\n* Subject with serum creatinine level ≥ 2 mg\u002FL at inclusion.\n* Subject receiving (or planned to receive) haemofiltration, extracorporeal membrane oxygenation, hemodialysis or peritoneal dialysis, molecular adsorbent recirculating system or any other exchange technique.\n* Subject receiving (or planned to receive) body cooling.\n* Subject death is deemed imminent and inevitable.\n* Reporting of first dosing advice (based on blood sampling) is not possible within 28 hours (\\*) after start treatment.\n* The subject is known or suspected to be pregnant.\n* The subject has a known allergy to the specific beta-lactam antibiotic.\n\n(\\*) The first (a posteriori) dose calculation and dose adjustment if necessary, is performed within a maximum timeframe of 28 hours after start of treatment (i.e. maximum timeframe to first dose adjustment).","0 Years","18 Years",{"count":81,"type":21},58,[83],"PHASE4","The overall objective of this study is to investigate the impact of early model-informed precision dosing (MIPD) on target attainment of three beta-lactam antibiotics (amoxicillin-clavulanic acid, piperacillin-tazobactam and meropenem) in critically ill children. This evaluation includes a comparison with the more standard approach on clinical and patient-oriented measures.",[28,29,30],[87,88,89,90,91,92],"amoxicillin-clavulanate","piperacillint-tazobactam","meropenem","model-informed precision dosing","dose calculator","critically ill children","NOT_YET_RECRUITING","2025-04-08",{"date":96,"type":40},"2025-04-16",{"date":98,"type":21},"2025-04-22",{"date":100,"type":21},"2027-10-01",{"name":46,"class":47}]